COLLEEN LIZEWSKI: Open Payments
NPI 1760804512 · NAGS HEAD, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,052 in 102 payments from 19 companies in 2025. Trend: 2023 $2,007 · 2024 $2,034 · 2025 $2,052
Food & beverage: $2,052
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $313 |
| Alkermes, Inc. | 11 | $268 |
| Otsuka America Pharmaceutical, Inc. | 11 | $223 |
| AstraZeneca Pharmaceuticals LP | 9 | $188 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $175 |
| ABBVIE INC. | 8 | $167 |
| Lilly USA, LLC | 6 | $111 |
| Teva Pharmaceuticals USA, Inc. | 5 | $94 |
| E.R. Squibb & Sons, L.L.C. | 4 | $92 |
| Aimmune Therapeutics, Inc. | 4 | $77 |
Products named: INGREZZA, LYBALVI, CAPLYTA, REXULTI, COBENFY, AIRSUPRA, ABILIFY ASIMTUFII, ZENPEP.
Industry payments across NC — which companies pay providers there.
